Compare CVS Health Corp (CVS) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Vanguard Short Term Corporate Bond ETF — how do they compare? CVS Health Corp trades at $85.29 (market cap $112.29B), while Vanguard Short Term Corporate Bond ETF trades at $77.34 (market cap $51.90B). The key difference: CVS Health Corp is far larger — about 2.2× Vanguard Short Term Corporate Bond ETF's market cap, and CVS Health Corp pays a 3.03% dividend while Vanguard Short Term Corporate Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Vanguard Short Term Corporate Bond ETF for 52 Days on average.
| CVS | VCSH | |
|---|---|---|
Market Cap | $112.29B | $51.90B |
Volume | 7,763,676 | 2,892,221 |
Sector | Health | Fixed Income |
52-Week High | $110.60 | $80.20 |
52-Week Low | $70.08 | $77.03 |
Typical Hold Time | 83 Days | 52 Days |
Enterprise Value | $174.64B | — |
Dividend Yield | 3.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 26% upside. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 estimate. Revenue growth remains solid at $402.07 billion for 2025, though net margins compressed to 1.18%. Technical indicators show a bullish overall signal with support at $87 and resistance at $89.
The outlook remains positive given CVS's dominant market position and Medicare expansion plans, but investors face risks from reimbursement pressures and ongoing legal investigations. Earnings growth and successful execution of healthcare services integration represent the primary catalysts for continued stock appreciation.
VCSH, the Vanguard Short-Term Corporate Bond ETF, trades at $77.27 with a slight 0.08% daily gain. Technical indicators show a bearish trend from moving averages, though oscillators are neutral. The ETF offers a competitive yield and low expense ratio, but faces headwinds from tight credit spreads and a cautious market outlook. Recent news highlights its role as a stable income alternative to CDs or stable value funds, with institutional activity showing mixed positioning.
The outlook for VCSH is neutral with limited upside due to unattractive entry points and constrained credit spreads. Its short duration minimizes interest rate risk, but yield advantages over peers may narrow. Key risks include corporate credit deterioration and Fed policy shifts. Investors seeking short-term, high-quality bond exposure may find value, but current levels offer modest total return potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
